Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmaceutical Shorla Oncology’s Cancer Treatment Approved by FDA
FDA

Shorla Oncology’s Cancer Treatment Approved by FDA

1st July 2024

The NDA for TEPYLUTE, an innovative medication used to treat breast and ovarian cancer, has been authorised by the FDA for specialty pharmaceutical business Shorla Oncology.

The drug, formerly known as SH-105, is an injection that is ready to dilute, making preparation easier and guaranteeing accurate dose for therapies for ovarian and breast cancer.

Shorla Oncology chief commercial officer Rayna Herman commented: “Among TEPYLUTE’s many benefits, it removes the necessity to reconstitute which can introduce additional risks of drug preparation errors.

Another addition to Shorla Oncology’s repertoire is SH-201, an appealing oral liquid therapy for specific forms of leukaemia and other malignancies.

SH-201 has been approved by the FDA for NDA assessment in April 2024, and the decision to approve it is expected by November 30.

Addressing orphan and paediatric malignancies, the business’s pipeline of oncology medicines aims at tackling unmet needs, medication shortages, and inadequate applicability for the targeted groups.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.